The Medical Letter on Drugs and Therapeutics
Some Drugs for COVID-19
April 6, 2020 (Issue: 1595)The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in treating it. Definitive answers are lacking,...more
- L Fang et al. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020 March 11 (epub).
- MA Sparks et al. The coronavirus conundrum: ACE2 and hypertension edition. Available at: www.nephjc.com/news/covidace2. Accessed April 16, 2020.
- M Vaduganathan et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020 March 30 (epub).
- P Zhang et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 2020 Apr 17 (epub).
- J Li et al. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol 2020 Apr 23 (epub).
- DM Bean et al. Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multisite UK acute hospital trust. MedRxiv 2020 Apr 11 (preprint).
- K Mackey et al. Risks and impact of angiotensin converting enzyme inhibitors or angiotensin receptor blockers on SARS-Co_V-2 infection in adults. A living systematic review. Ann Intern Med 2020 May 15 (epub).
- ACC. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. Available at: https://bit.ly/2UiMyt6. Accessed April 16, 2020.
- M Day. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ 2020; 368:m1086.
- FDA. FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. Available at: https://bit.ly/3dnggWX. Accessed April 16, 2020.
- C Harrison. Coronavirus puts drug repurposing on the fast track. Available at: www.nature.com/articles/d41587-020-00003-1. Accessed April 16, 2020.
- B Cao et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020 March 18 (epub).
- RL Woosley and KA Romero. QT drugs list. Available at www.crediblemeds.org. Accessed April 16, 2020.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2019 November 6 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- NIH. Potential Antiviral Drugs Under Evaluation for the Treatment of COVID-19. Available at: https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/. Accessed May 26, 2020.
- W Alhazzani et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Available at: https://bit.ly/33KvsJj. Accessed April 16, 2020.
- A Bhimraj et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Available at: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Accessed April 16, 2020.
- IFN Hung et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to the hospital with COVID-19: an open-label, randomized, phase 2 trial. Lancet 2020 May 8 (epub).
- MR Mehra et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020 May 22 (epub).
- M Mahevas et al. Clinical efficacy of hydroxychloroquine in patients with COVID-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020; May 14 (epub).
- J Magagnoli et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. Medrxiv 2020 (epub) Available at: https://www.medrxiv.org/content/10.1101/2020.04.16.20065920v2. Accessed May 21, 2020.
- J Geleris et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020 May 7 (epub).
- DM Roden et al. Drug interactions on QTc in exploratory COVID-19 treatment. Circulation 2020 April 8 (epub).
- D Juurlink. Safety conditions with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ 2020 April 8 (epub).
- Post-exposure prophylaxis or preemptive treatment for SARS-Coronavirus-2. Available at: https://covidpep.umn.edu/. Accessed May 21, 2020.
- WHO. Clinical management of severe acute respiratory infection when COVID-19 is suspected. Interim guidance. Available at: https://bit.ly/2YjCKmy. Accessed April 16, 2020.
- CDC. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. Accessed April 16, 2020.
- C Wu et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020 Mar 13 (epub).
- Y Wang et al. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. medRxiv. 2020 Mar 6 (epub).
- Sanofi. Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients. Available at: https://bit.ly/3f24XnG. Accessed: April 29, 2020.
- S Murthy et al. Care for critically ill patients with COVID-19. JAMA 2020 March 11 (epub).
- ML Agostini et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is medicated by the viral polymerase and the proofreading exoribonuclease. mBio 2018; 9:e00221.
- J Grein et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020 April 10 (epub).
- Gilead. Gilead Sciences statement on positive data emerging from National Institute of Allergy and Infectious Diseases' Study of investigational antiviral remdesivir for COVID-19. Available at: https://bit.ly/2Ypkc42. Accessed: April 29, 2020.
- EM Bloch et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020 April 7 (epub).
- C Shen et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020 March 27 (epub).
- K Duan et al. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. medRxiv 2020 March 16.
- FDA. Investigational COVID-19 convalescent plasma-emergency IND. Available at: https://bit.ly/2ySGCQE. Accessed April 16, 2020.
- A Casadevall and LA Pirofski. The convalescent sera option for containing COVID-19. J Clin Invest 2020 March 13 (epub).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.